Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
54
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sorrento Therapeutics, Inc.